ABL Diagnostics Signs Letter of Intent for Reverse Merger with ProPhase Labs
ABL Diagnostics announces the signing of a non-binding letter of intent between its controlling shareholder ABL S.A. and the Nasdaq-listed American company ProPhase Labs, aimed at a reverse merger project. According to the statement, ABL would become the majority shareholder of the combined entity resulting from this transaction.
Preliminary Agreement Details
The letter of intent signed between Advanced Biological Laboratories S.A., the controlling shareholder of ABL Diagnostics, and ProPhase Labs is preliminary in nature, the company states. The document does not carry any obligation to conclude the transaction, except for usual provisions relating to confidentiality and cost coverage. The project remains subject to several conditions, according to the group, including the completion of due diligence, negotiation and signing of definitive agreements, obtaining regulatory approvals, and meeting Nasdaq listing requirements. The parties aim for a timeline of 60 to 90 days to sign the definitive agreements, as per the statement. In the absence of signing definitive agreements, each party will continue its operations independently.
Impact on Corporate Control and Regulatory Requirements
Based on the information available, the project does not affect the control of ABL Diagnostics by ABL S.A. and does not trigger a mandatory public offer threshold, the company indicates. However, ABL Diagnostics states that it will review all aspects of the transaction with its advisors and, if necessary, will notify the Financial Markets Authority and seek an exemption. On the American side, the transaction may require the approval of ProPhase shareholders in case of a change of control or an issuance of shares exceeding 20 percent of the capital, the statement specifies. ProPhase remains responsible for its compliance with Nasdaq and Securities and Exchange Commission regulations.
Details about ProPhase Labs and the Proposed Transaction
ProPhase Labs is an American company listed on Nasdaq under the ticker PRPH. The proposed transaction would take the form of a reverse merger, a financial technique whereby an unlisted company takes control of a listed company, thus allowing the former to access the financial markets. In this case, ABL would become the majority shareholder of the entity resulting from the merger, according to the statement. ABL Diagnostics, headquartered in Woippy, France, specializes in innovative molecular biology testing and markets its product range globally. The company is listed on compartment B of the regulated market of Euronext in Paris.
